Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry
| العنوان: | Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry |
|---|---|
| المؤلفون: | Reid C. Gallant, Philip Britz-McKibbin, Hamzah Khan, Muzammil H. Syed, Mohammad Qadura, Meera Shanmuganathan, Shubha Jain, Sherri Afxentiou, Margaret L. Rand, Mohammed Al-Omran, Zachary Kroezen, Abdelrahman Zamzam, Heyu Ni |
| المصدر: | Diagnostics Diagnostics, Vol 10, Iss 871, p 871 (2020) Volume 10 Issue 11 |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Dose, aspirin, Urinary system, Clinical Biochemistry, 030204 cardiovascular system & hematology, Gastroenterology, Article, resistance, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Platelet, anti-platelet, Aspirin, lcsh:R5-920, business.industry, personalized medicine, Salicyluric acid, medicine.disease, digestive system diseases, Stenosis, 030104 developmental biology, surgical procedures, operative, chemistry, Ambulatory, non-sensitivity, atherosclerosis, business, lcsh:Medicine (General), light transmission aggregometry, Ex vivo, medicine.drug |
| الوصف: | Acetylsalicylic acid (ASA), also known as aspirin, appears to be ineffective in inhibiting platelet aggregation in 20&ndash 30% of patients. Light transmission aggregometry (LTA) is a gold standard platelet function assay. In this pilot study, we used LTA to personalize ASA therapy ex vivo in atherosclerotic patients. Patients were recruited who were on 81 mg ASA, presenting to ambulatory clinics at St. Michael&rsquo s Hospital (n = 64), with evidence of atherosclerotic disease defined as clinical symptoms and diagnostic findings indicative of symptomatic peripheral arterial disease (PAD), with an ankle brachial index (ABI) of < 0.9 (n = 52) or had diagnostic features of asymptomatic carotid arterial stenosis (CAS), with > 50% stenosis of internal carotid artery on duplex ultrasound (n = 12). ASA compliance was assessed via multisegmented injection-capillary electrophoresis-mass spectrometry based on measuring the predominant urinary ASA metabolite, salicyluric acid. LTA with arachidonic acid was used to test for ASA sensitivity. Escalating ASA dosages of 162 mg and 325 mg were investigated ex vivo for ASA dose personalization. Of the 64 atherosclerotic patients recruited, 8 patients (13%) were non-compliant with ASA. Of ASA compliant patients (n = 56), 9 patients (14%) were non-sensitive to their 81 mg ASA dosage. Personalizing ASA therapy in 81 mg ASA non-sensitive patients with escalating dosages of ASA demonstrated that 6 patients became sensitive to a dosage equivalent to 162 mg ASA and 3 patients became sensitive to a dosage equivalent to 325 mg ASA. We were able to personalize ASA dosage ex vivo in all ASA non-sensitive patients with escalating dosages of ASA within 1 h of testing. |
| وصف الملف: | application/pdf |
| تدمد: | 2075-4418 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ab2fd795e231162b0c8c8c60ec4047Test https://pubmed.ncbi.nlm.nih.gov/33114560Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....39ab2fd795e231162b0c8c8c60ec4047 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20754418 |
|---|